Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Gene expression data of human hepatocellular carcinoma (HCC)

ABSTRACT: We used Affymetrix microarray profiling to analyze gene expression patterns in healthy donor liver as well as tumor and paired non-tumor tissue of HCC patients. For gene expression profiling, tumors and paired non-tumor tissues were profiled separately using a single channel array platform. Tumor and paired non-tumor samples of 22 patients of cohort1 and the normal liver pool were carried out on Affymetrix GeneChip HG-U133A 2.0 arrays (Affymetrix, Santa Clara, CA) according to the manufacturer's protocol. The fluorescent intensities were determined with an Affymetrix GeneChip Scanner 3000, controlled by GCOS Affymetrix software. All samples of cohort2 and 42 tumor and paired non-tumor samples of cohort2 were processed on the 96 HT HG-U133A microarray platform. The fluorescent intensities were determined with an Affymetrix GeneChip HT Array Plate Scanner, controlled by GCOS Affymetrix software. Cohort 1 Training Group: LCS-005A, LCS-019A, LCS-029A, LCS-039A, LCS-039B, LCS-254A, LCS-254B, LCS-068A, LCS-068B, LCS-076A, LCS-076B, LCS-004A, LCS-004B, LCS-007A, LCS-007B, LCS-024B, LCS-042B, LCS-062B, LCS-023A, LCS-023B, LCS-067A, LCS-065A, LCS-073A, LCS-067B, LCS-065B, LCS-073B, LCS-024A, LCS-042A, LCS-062A, LCS-015A, LCS-069A, LCS-015B, LCS-069B, LCS-033A, LCS-061A, LCS-020A, LCS-045A, LCS-033B, LCS-020B, LCS-045B, LCS-057A, LCS-009A, LCS-057B, LCS-009B, LCS-049A, LCS-049B, LCS-061B, LCS-047A, LCS-047B, LCS-075A, LCS-075B, LCS-034A, LCS-034B, LCS-041A, LCS-041B, LCS-044A, LCS-044B, LCS-071A, LCS-071B, LCS-036A, LCS-064A, LCS-064B, LCS-038A, LCS-038B, LCS-002A, LCS-028B, LCS-016B, LCS-054A, LCS-063A, LCS-022A, LCS-054B, LCS-063B, LCS-022B, LCS-036B, LCS-025A, LCS-066A, LCS-027A, LCS-048A, LCS-012A, LCS-025B, LCS-066B, LCS-027B, LCS-048B, LCS-012B, LCS-051A, LCS-056A, LCS-051B, LCS-056B, LCS-028A, LCS-016A, LCS-196A, LCS-196B, LCS-072A, LCS-072B, LCS-333A, LCS-333B, LCS-339A, LCS-339B, LCS-341A, LCS-341B, LCS-343A, LCS-343B, LCS-344A, LCS-344B, LCS-346A, LCS-346B, LCS-347A, LCS-347B, LCS-393A, LCS-393B, LCS-400A, LCS-400B, LCS-401A, LCS-401B, LCS-403A, LCS-403B, LCS-406A, LCS-406B, LCS-415A, LCS-415B, LCS-424A, LCS-424B, LCS-426A, LCS-426B Cohort 2 Testing Group: LCS-079A, LCS-092A, LCS-101A, LCS-079B, LCS-092B, LCS-101B, LCS-083A, LCS-095A, LCS-102A, LCS-083B, LCS-095B, LCS-102B, LCS-085A, LCS-096A, LCS-103A, LCS-085B, LCS-096B, LCS-103B, LCS-091A, LCS-099A, LCS-105A, LCS-091B, LCS-099B, LCS-105B, LCS-122A, LCS-130A, LCS-123A, LCS-135A, LCS-123B, LCS-135B, LCS-125A, LCS-127A, LCS-136A, LCS-125B, LCS-127B, LCS-136B, LCS-122B, LCS-130B, LCS-212B, LCS-180B, LCS-183B, LCS-153B, LCS-018B, LCS-188A, LCS-185A, LCS-154A, LCS-120A, LCS-286A, LCS-086A, LCS-177A, LCS-140A, LCS-035A, LCS-188B, LCS-185B, LCS-154B, LCS-120B, LCS-286B, LCS-238B, LCS-086B, LCS-177B, LCS-035B, LCS-275B, LCS-132A, LCS-205A, LCS-274A, LCS-159A, LCS-150A, LCS-014A, LCS-227A, LCS-283A, LCS-162A, LCS-104A, LCS-272A, LCS-132B, LCS-205B, LCS-274B, LCS-159B, LCS-227B, LCS-046B, LCS-283B, LCS-272B, LCS-237A, LCS-152A, LCS-209A, LCS-211A, LCS-230A, LCS-262A, LCS-144A, LCS-158B, LCS-237B, LCS-152B, LCS-209B, LCS-211B, LCS-230B, LCS-262B, LCS-144B, LCS-212A, LCS-180A, LCS-183A, LCS-153A, LCS-018A, LCS-275A, LCS-118A, LCS-234A, LCS-210A, LCS-265A, LCS-149A, LCS-040A, LCS-169A, LCS-256A, LCS-190B, LCS-118B, LCS-234B, LCS-210B, LCS-265B, LCS-149B, LCS-040B, LCS-169B, LCS-213A, LCS-164A, LCS-223A, LCS-245A, LCS-281B, LCS-191A, LCS-171A, LCS-249A, LCS-213B, LCS-164B, LCS-245B, LCS-094B, LCS-094A, LCS-191B, LCS-171B, LCS-249B, LCS-131A, LCS-241A, LCS-074A, LCS-160A, LCS-179A, LCS-134A, LCS-224A, LCS-078A, LCS-131B, LCS-201B, LCS-074B, LCS-160B, LCS-179B, LCS-134B, LCS-147B, LCS-224B, LCS-078B, LCS-093A, LCS-253A, LCS-279A, LCS-008A, LCS-291A, LCS-281A, LCS-156A, LCS-282A, LCS-090A, LCS-151A, LCS-253B, LCS-279B, LCS-008B, LCS-172B, LCS-291B, LCS-156B, LCS-282B, LCS-090B, LCS-151B, LCS-259A, LCS-010A, LCS-264A, LCS-264B, LCS-163A, LCS-163B, LCS-089A, LCS-089B, LCS-143A, LCS-143B, LCS-199A, LCS-199B, LCS-278A, LCS-278B, LCS-119A, LCS-119B, LCS-184A, LCS-184B, LCS-203A, LCS-203B, LCS-178A, LCS-178B, LCS-284A, LCS-284B, LCS-108A, LCS-261B, LCS-043A, LCS-043B, LCS-174A, LCS-174B, LCS-166A, LCS-193A, LCS-193B, LCS-215A, LCS-215B, LCS-021A, LCS-021B, LCS-129A, LCS-129B, LCS-198A, LCS-198B, LCS-084A, LCS-084B, LCS-250A, LCS-011A, LCS-108B, LCS-011B, LCS-219A, LCS-219B, LCS-194A, LCS-194B, LCS-170A, LCS-170B, LCS-204A, LCS-204B, LCS-261A, LCS-195A, LCS-195B, LCS-200B, LCS-206A, LCS-206B, LCS-161B, LCS-145A, LCS-145B, LCS-236A, LCS-236B, LCS-270A, LCS-270B, LCS-182A, LCS-182B, LCS-197B, LCS-173B, LCS-240B, LCS-266B, LCS-167B, LCS-032B, LCS-050B, LCS-285B, LCS-031B, LCS-189A, LCS-277A, LCS-117A, LCS-267A, LCS-100A, LCS-228A, LCS-268A, LCS-222A, LCS-192A, LCS-175A, LCS-277B, LCS-117B, LCS-267B, LCS-100B, LCS-228B, LCS-268B, LCS-222B, LCS-192B, LCS-248A, LCS-121A, LCS-157A, LCS-148A, LCS-126A, LCS-260A, LCS-223B, LCS-121B, LCS-157B, LCS-148B, LCS-260B, LCS-247A, LCS-088A, LCS-243A, LCS-165A, LCS-208A, LCS-110A, LCS-146A, LCS-247B, LCS-243B, LCS-165B, LCS-208B, LCS-110B, LCS-146B, LCS-147A, LCS-173A, LCS-240A, LCS-266A, LCS-167A, LCS-032A, LCS-050A, LCS-285A, LCS-031A, LCS-106A, LCS-106B, LCS-107A, LCS-107B, LCS-109A, LCS-109B, LCS-116A, LCS-137A, LCS-137B, LCS-138A, LCS-138B, LCS-139A, LCS-139B, LCS-142A, LCS-142B, LCS-207A, LCS-231A, LCS-231B, LCS-251A, LCS-263A, LCS-263B, LCS-269A, LCS-269B, LCS-273A, LCS-273B, LCS-289A, LCS-289B, LCS-290A, LCS-290B, LCS-093B, LCS-097A, LCS-097B, LCS-104B, LCS-140B, LCS-150B, LCS-158A, LCS-161A, LCS-162B, LCS-014B, LCS-166B, LCS-172A, LCS-197A, LCS-200A, LCS-201A, LCS-216A, LCS-216B, LCS-238A, LCS-241B, LCS-046A, LCS-248B, LCS-259B, Normal1, Normal2, LCS-003B, LCS-006B, LCS-026B, LCS-128B, LCS-168B, LCS-181B, LCS-190A, X02-342A, X02-342B, X02-362A, X02-362B

ORGANISM(S): Homo sapiens

SUBMITTER: Xin Wang

PROVIDER: E-GEOD-14520 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.

Roessler Stephanie S Jia Hu-Liang HL Budhu Anuradha A Forgues Marshonna M Ye Qing-Hai QH Lee Ju-Seog JS Thorgeirsson Snorri S SS Sun Zhongtang Z Tang Zhao-You ZY Qin Lun-Xiu LX Wang Xin Wei XW

Cancer research 20101201 24

Metastasis-related recurrence often occurs in hepatocellular carcinoma (HCC) patients who receive curative therapies. At present, it is challenging to identify patients with high risk of recurrence, which would warrant additional therapies. In this study, we sought to analyze a recently developed metastasis-related gene signature for its utility in predicting HCC survival, using 2 independent cohorts consisting of a total of 386 patients who received radical resection. Cohort 1 contained 247 pre ...[more]

PMID: 21159642

Publication: 1/2

Similar Datasets

Project description:Langerhans cells (LCs) are antigen presenting cells residing in the epidermis. Due to the difficulties with obtaining sufficient quantities of LCs for functional studies, many controversies exist about their origin and function. To gain insights into the molecular mechanisms underpinning LC biology and to elucidate how similar they are to a classical tissue resident DCs of myeloid origin, we undertook a whole transcriptome analysis of human skin migratory CD1a+ LCs and CD11c+ DDCs, stimulated with an epidermal pro-inflammatory cytokine, TNF-α over a time course of 24h. RNA was extracted from 250,000 human skin migratory CD1a+ LCs and CD11c+ DDCs stimulated in culture with 25ng/ml of TNF-α for 0, 2, 8 and 24h. RNA concentration and integrity was determined with an Agilent Bioanalyser (RIN of 7.0 or above) and gene expression analysis was carried out using the Human Genome U-219 Affymetrix platform by ARK-Genomics Centre, The Roslin Institute, Edinburgh. Expression data were normalised using the Robust Multichip Average (RMA) package. 2,334 transcripts regulated by exposure of skin DCs to TNF-α were identified with Bayesian Estimation of Temporal Regulation, a cut-off threshold 0.05 , for genes showing ≥ 1.5 fold difference between the maximum gene expression level and time 0 control in log2(x) RMA normalised gene expression. The interactive 3D diagram presenting the transcriptomic networks in human skin DCs can be viewed at: http://www.macrophages.com/LC_vs_DC RNA was extracted from 250,000 human skin migratory CD1a+ LCs and DDCs stimulated in culture with 25ng/ml of TNF-α for 0, 2, 8 and 24h. RNA concentration and integrity was determined with an Agilent Bioanalyser (RIN of 7.0 or above) and gene expression analysis was carried out using the Human Genome U-219 Affymetrix platform by ARK-Genomics Centre, The Roslin Institute, Edinburgh. Expression data were normalised using the Robust Multichip Average (RMA) package. 2,334 transcripts regulated by exposure of skin DCs to TNF-α were identified with Bayesian Estimation of Temporal Regulation, a cut-off threshold 0.05 , for genes showing ≥ 1.5 fold difference between the maximum gene expression level and time 0 control in log2(x) RMA normalised gene expression. *submitter cannot locate the CEL files

Project description:To compare human memory CD4+ T cell subsets in peripheral blood (PB) and bone marrow (BM) of healthy individuals at transcriptional level, we analyzed the global gene expression of ex vivo PB CD69- as well as BM CD69- and CD69+ memory CD4+ T cells from 4 paired PB and BM samples. The gene expression of these subsets was additionally compared to the transcriptional profile of 8 PB samples taken ex vivo or stimulated with phorbol myristate acetate (PMA) and Ionomycin for 3 hours. Three ex vivo memory CD4+ T cell subsets (CD4+CD45RO+CD69+ and CD4+CD45RO+CD69- cells from bone marrow; CD4+CD45RO+CD69- cells from peripheral blood) were isolated from 4 paired bone marrow and blood samples (two males and two females) or from a different cohort of 8 blood samples (3 males and five females). The purity of sorted cells was higher than 95% as assessed by FACS. Subsequently, a fraction of purified cells from the 8 blood samples were stimulated with phorbol-myristic-acid/ionomycin (PMA/iono) for 3 h and used as high controls. Total RNA of each cell subset was extracted using a NucleoSpin RNA XS Kit (Macherey-Nagel) or RNeasy Mini kit (Qiagen). The integrity and amount of isolated RNA was assessed for each sample using an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Double-stranded complementary RNA was synthesized from 1 M-BM-5g total RNA using Message AmpII Biotin (Ambion, USA). Fifteen micrograms of fragmented cRNA of each sample were hybridized to 28 HG-U133A plus 2.0 GeneChips (Affymetrix). Hybridization was performed in a Hybridization Oven 640, and chips were washed and stained in the Fluidics Station 400 (both Affymetrix). Finally, the arrays were scanned with a GeneChip Scanner 3000 using the GCOS software, version 1.4, both Affymetrix. All relevant GCOS data of quality checked microarrays were analyzed with High Performance Chip Data Analysis (HPCDA, unpublished), using the BioRetis database (www.bioretis-analysis.de), as described and validated previously.

Dataset Information

Gene expression data of human hepatocellular carcinoma (HCC)

Publications

A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure